These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35348374)

  • 1. Patients undergoing multiple
    Indrakanti S; Li X; Rehani MM
    Br J Radiol; 2022 Jul; 95(1135):20211225. PubMed ID: 35348374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma.
    Heckmann MB; Totakhel B; Finke D; Anker MS; Müller-Tidow C; Haberkorn U; Katus HA; Lehmann LH
    ESC Heart Fail; 2019 Aug; 6(4):824-829. PubMed ID: 31278857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of
    Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
    Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic reference levels for
    Alkhybari EM; McEntee MF; Brennan PC; Willowson KP; Kench PL
    J Med Imaging Radiat Oncol; 2019 Jun; 63(3):291-299. PubMed ID: 30770654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
    Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
    Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
    Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
    Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of
    Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
    Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients.
    Atkinson W; Catana C; Abramson JS; Arabasz G; McDermott S; Catalano O; Muse V; Blake MA; Barnes J; Shelly M; Hochberg E; Rosen BR; Guimaraes AR
    Abdom Radiol (NY); 2016 Jul; 41(7):1338-48. PubMed ID: 27315095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma.
    Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Cho H; Chung H; Min YH; Yang WI; Cho A; Kim JS
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S245-S252. PubMed ID: 32550718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
    Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
    Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body MRI versus an [
    Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; de Keizer B; Nievelstein RAJ
    Eur Radiol; 2021 Dec; 31(12):8925-8936. PubMed ID: 34021390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
    Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
    Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
    Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.
    Alkhawtani RHM; Noordzij W; Glaudemans AWJM; van Rijn RS; van der Galiën HT; Balink H; Nijland M; Adams HJA; Huls G; van Meerten T; Kwee TC
    Nucl Med Commun; 2018 Jun; 39(6):572-578. PubMed ID: 29672465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-therapy lesions in patients with non-Hodgkin's lymphoma characterized by 18F-FDG PET/CT-guided biopsy using automated robotic biopsy arm.
    Radhakrishnan RK; Mittal BR; Basher RK; Prakash G; Malhotra P; Kalra N; Das A
    Nucl Med Commun; 2018 Jan; 39(1):74-82. PubMed ID: 29189443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.